

News Release

February 25, 2022

Progress of Innovative Drug Discovery Research Collaboration with HitGen

Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office: Chuo-ku, Osaka, Japan; President & Representative Director: Hiroaki Ueno) announced that MTPC concluded a drug discovery research collaboration with HitGen Inc. (Head Office: Chengdu, China; Chairman & CEO: Jin Li) for the discovery of seed compounds for drug discovery target molecules in December 2018, and the agreement expired in December 2021.

In the three-year collaborative research, several drug discovery target molecules were screened against HitGen's original next-generation compound library (DNA encoded chemical libraries: DELs), comprising more than 1 trillion compounds. We were able to obtain seed compounds for several target molecules. MTPC will create hit compounds and lead compounds through compound development. As part of MTPC's growth strategy to realize "VISION 30", which was formulated as MTPC's company vision for 2030, MTPC is focusing on "Precision Medicine", MTPC is advancing drug discovery research with the goal of creating breakthrough drugs.

MTPC will continue to take on the challenge of creating innovative drugs that meet unmet medical needs through open innovation with various partners.

Mitsubishi Tanabe Pharma Corporation
Communication Crossroads Department

Media contacts: TEL: +81 6 6205 5119

A member of Mitsubishi Chemical Holdings Group.

KAITEKI Value for Tomorrow
Mitsubishi Chemical Holdings Group

■ About HitGen Inc.

HitGen Inc. is a biotech company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. It became a publicly listed company in Shanghai Stock Exchange in April 2020 (ticker code 688222.SH). HitGen has established a drug discovery research platform for small molecules and nucleic acid drug centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen's DELs currently contains more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many thousands of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.

For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.